CN104017057A - 一种st2蛋白抑制剂多肽及其应用 - Google Patents
一种st2蛋白抑制剂多肽及其应用 Download PDFInfo
- Publication number
- CN104017057A CN104017057A CN201410293555.XA CN201410293555A CN104017057A CN 104017057 A CN104017057 A CN 104017057A CN 201410293555 A CN201410293555 A CN 201410293555A CN 104017057 A CN104017057 A CN 104017057A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- cell
- inhibitor polypeptide
- protein inhibitor
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410293555.XA CN104017057B (zh) | 2014-06-27 | 2014-06-27 | 一种st2蛋白抑制剂多肽及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410293555.XA CN104017057B (zh) | 2014-06-27 | 2014-06-27 | 一种st2蛋白抑制剂多肽及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104017057A true CN104017057A (zh) | 2014-09-03 |
CN104017057B CN104017057B (zh) | 2016-08-24 |
Family
ID=51434100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410293555.XA Expired - Fee Related CN104017057B (zh) | 2014-06-27 | 2014-06-27 | 一种st2蛋白抑制剂多肽及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104017057B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001070817A1 (fr) * | 2000-03-21 | 2001-09-27 | Medical & Biological Laboratories Co., Ltd. | Anticorps monoclonal et methode et kit d'immunodosage de st2 humaine soluble l'utilisant |
CN103796669A (zh) * | 2011-07-18 | 2014-05-14 | 重症监护诊断股份有限公司 | 治疗心血管疾病和预测运动疗法功效的方法 |
-
2014
- 2014-06-27 CN CN201410293555.XA patent/CN104017057B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001070817A1 (fr) * | 2000-03-21 | 2001-09-27 | Medical & Biological Laboratories Co., Ltd. | Anticorps monoclonal et methode et kit d'immunodosage de st2 humaine soluble l'utilisant |
CN103796669A (zh) * | 2011-07-18 | 2014-05-14 | 重症监护诊断股份有限公司 | 治疗心血管疾病和预测运动疗法功效的方法 |
Non-Patent Citations (2)
Title |
---|
MARIJA MILOVANOVIC ET AL.: "IL-33/ST2 axis in inflammation and immunopathology", 《IMMUNOL RES》, vol. 52, 6 March 2012 (2012-03-06), pages 89 - 99, XP035044245, DOI: doi:10.1007/s12026-012-8283-9 * |
白芳芸等: "ST2蛋白在胃癌中的表达及意义", 《中国现代医学杂志》, vol. 22, no. 11, 30 April 2012 (2012-04-30), pages 48 - 52 * |
Also Published As
Publication number | Publication date |
---|---|
CN104017057B (zh) | 2016-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Samarpita et al. | Cyanidin prevents the hyperproliferative potential of fibroblast-like synoviocytes and disease progression via targeting IL-17A cytokine signalling in rheumatoid arthritis | |
CN103371991A (zh) | 二甲双胍在制备预防或治疗肝细胞癌药物中的应用 | |
Sodani et al. | Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis | |
Zhang et al. | Astragalus polysaccharides attenuate pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition and NF-κB pathway activation | |
Ma et al. | Topical application of temperature-sensitive caerin 1.1 and 1.9 gel inhibits TC-1 tumor growth in mice | |
CN113599527B (zh) | Apoe抑制剂与pd-1单抗联用在制备治疗消化道肿瘤的药物中的应用 | |
CN107446022A (zh) | 一种可拮抗parp1蛋白rna结合活性的多肽pip‑14及其应用 | |
CN104017057A (zh) | 一种st2蛋白抑制剂多肽及其应用 | |
CN104017055B (zh) | 一种关于st2蛋白抑制剂多肽及其应用 | |
CN104059130A (zh) | 关于st2蛋白抑制剂多肽及其应用 | |
CN115581762A (zh) | 一种用于清除hpv病毒感染的医用生物蛋白修复凝胶及其制备方法 | |
Guan et al. | Treatment of consistent BRAF/HRAS gene mutation and MYC amplification radiation-induced abdominal wall angiosarcoma with low-dose apatinib: a case report | |
CN102727799A (zh) | 用于治疗女性子宫颈糜烂的中药组合物 | |
CN103933044B (zh) | 一种治疗肿瘤的药物组合物及用途 | |
CN104017056B (zh) | St2蛋白抑制剂多肽及其应用 | |
CN104478822B (zh) | 一种治疗骨质疏松的药物组合物 | |
CN113768924B (zh) | 一种能抑制肿瘤细胞的组合物及其相关应用 | |
CN104013625A (zh) | 一种治疗疣疾病的组合药物 | |
CN111973745B (zh) | Bap18在乳腺癌内分泌治疗抵抗中的应用 | |
CN115501231B (zh) | 预防和/或治疗肝癌的联用药物组合物及其应用 | |
NL2032826B1 (en) | APPLICATION OF TLR4-activated EXOSOME OR EXOSOME PREPARATION IN PREPARING DRUG FOR PREVENTING AND TREATING RADIATION-INDUCED LUNG INJURY | |
RU2499594C1 (ru) | Способ лечения хронического эндометрита | |
CN104086630B (zh) | 一种生长抑素受体激动剂多肽及其应用 | |
Kew et al. | Infection of a lymphocyst after pelvic lymph node dissection for endocervical adenocarcinoma | |
Ordiyants et al. | Recurrence of HPV infection after combination therapy of uterine cervical diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Kang Wei Inventor after: Ma Qingxiang Inventor after: Li Guang Inventor after: Kang Kai Inventor after: Peng Yuping Inventor before: Luo Ruixue |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160701 Address after: 719000, 93, Yu Xi Road, Yulin hi tech Development Zone, Shaanxi, Yulin Applicant after: Yulin City First Hospital Address before: High tech Zone Suzhou city Jiangsu province 215000 Chuk Yuen Road No. 209 Applicant before: Suzhou Pu Luo Da Biotechnology Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160824 Termination date: 20170627 |
|
CF01 | Termination of patent right due to non-payment of annual fee |